Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Q BioMed Inc QBIO

Healthcare Biotechnology
Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated... see more

Recent & Breaking News (GREY:QBIO)

Q BioMed Inc. to Present at 30th Annual Roth Conference, Taking Place March 11-14, 2018, in Dana Point, CA

PR Newswire March 9, 2018

Q Biomed Inc. Signs Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma

PR Newswire February 8, 2018

Q Biomed Inc. Closes $5.48 Million Public Offering

PR Newswire February 1, 2018

Q BioMed Inc. Prices $5.5 Million Public Offering

PR Newswire January 30, 2018

Q Biomed Inc. to Present at Biotech Showcase(™) 2018

PR Newswire January 3, 2018

Q BioMed Provides Year End Update

PR Newswire December 21, 2017

Q BioMed Announces Full Settlement of All Convertible Debt

PR Newswire December 5, 2017

Q BioMed Adds Boston University's Dr. Tager-Flusberg to Advisory Committee

PR Newswire November 28, 2017

Q Biomed Inc. Announces Funding to Technology Partner Mannin Research Inc. to Expand Product Pipeline

PR Newswire November 14, 2017

Q BioMed Announces Identification and Production of New Proprietary Drug Candidate for Pediatric Nonverbal Disorder

PR Newswire October 19, 2017

Q BioMed Announces Favorable Amendment to Debenture Financing

PR Newswire October 12, 2017

Q BioMed Announces Launch of PainFreeCancer.com Website in Support of Non-Opioid Cancer Pain Drug

PR Newswire October 5, 2017

Q BioMed Announces Development Partnership With Sphaera Pharma

PR Newswire September 19, 2017

Q BioMed Inc. Closes $3,050,390 Equity Financing

PR Newswire August 2, 2017

Q BioMed Inc. to be Featured on CEO Clips Airing on Bloomberg Television

PR Newswire July 10, 2017

Q BioMed Inc., New Drug Application, CEO Clip Video

Newsfile July 7, 2017

Q BioMed Inc. Adds Nuclear Medicine Industry Veteran to Commercialization Team

PR Newswire June 26, 2017

Q BioMed Inc. Finalizes License Agreement With Oklahoma Medical Research Foundation and the Rajiv Gandhi Centre for Biotechnology for Novel Liver Cancer Treatment

PR Newswire June 15, 2017

Q BioMed Inc. to Present at the Sixth Annual Marcum Microcap Conference in New York

PR Newswire June 14, 2017

Q BioMed Announces Attendance at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

PR Newswire June 9, 2017